Parkinson's disease coverage on Peptide News Digest sits at the intersection of GLP-1 secondary indications and traditional peptide neurology programs. Several GLP-1 agonist trials in Parkinson's (separate from the Alzheimer's EVOKE program) have shown disease-modifying signals in early-phase work.
The AAN 2026 living systematic review covered Parkinson's alongside Alzheimer's, multiple sclerosis, and stroke as part of the GLP-1 repositioning landscape. The mechanism work — GLP-1 receptors on dopaminergic neurons, neuroinflammation modulation — is suggestive but the Phase 3 data is still pending in PD specifically.
A second peptide approach targets alpha-synuclein directly. AC Immune's ACI-7104, a vaccine built on an eight-amino-acid peptide that mimics part of alpha-synuclein, met its week-100 safety and immunogenicity endpoints in Part 1 of the Phase 2 VacSYn trial (34 patients, randomized 3:1) on September 23, 2026. The company said all patients developed antibodies to the PD01 antigen after three doses, but the trial has not yet shown a clinical benefit; AC Immune plans to meet the FDA in early 2027 before an expanded Phase 2.
Stories here cover trial readouts and the registry data that contextualize them. See #neurology and #neurodegeneration for adjacent threads.
Researchers at China Pharmaceutical University reported in Advanced Functional Materials on October 22, 2026 a leucine zipper-inspired peptide that binds the protein VHL, packed into a lipid nanocomplex carrying the T7 targeting peptide so that it reaches dopamine-producing neurons and their mitochondria. Given systemically, the complex reached those neurons within two hours, released the peptide in acidic conditions, and disrupted VHL's interaction with DVL-2, raising β-catenin and hexokinase 2 and improving mitochondrial energy production. Treatment reduced neurodegeneration and motor and coordination deficits in both an MPTP toxin model and an α-synuclein overexpression model; the work is preclinical.
Researchers at the University of Rouen Normandy and Inserm reported in Frontiers in Pharmacology on October 21, 2026 that a single 10-nanogram injection into the brain's ventricles of OP, an analog of octadecaneuropeptide (ODN), a peptide made by astrocytes, prevented the loss of dopamine-producing neurons in mice given the toxin MPTP. The peptide reduced oxidative damage, lowered the inflammatory marker TNF-α while raising IL-10, and preserved tight-junction proteins of the blood-brain barrier, assessed seven days after the toxin. The work is in an acute mouse model, and the peptide was delivered directly into the brain.
AC Immune reported on September 23, 2026 that Part 1 of VacSYn, a randomized, double-blind, placebo-controlled Phase 2 trial in early Parkinson's disease, met all of its primary safety, tolerability, and immunogenicity endpoints through week 100. Thirty-four patients were randomized 3:1 to ACI-7104 or placebo; the company said 100% of patients developed antibodies against the PD01 antigen after three immunizations, antibodies reached the cerebrospinal fluid in all patients, and the vaccine was generally safe and well tolerated. ACI-7104.056 uses an eight-amino-acid peptide that mimics a C-terminal alpha-synuclein epitope, conjugated to keyhole limpet hemocyanin, according to Alzforum. AC Immune reported a CSF total alpha-synuclein signal consistent with target engagement but no clinical efficacy result, and plans FDA meetings in early 2027 before an expanded Phase 2.
A comprehensive NeurologyLive review details emerging evidence for GLP-1 receptor agonists across neurological diseases including Alzheimer's, Parkinson's, multiple sclerosis, and stroke. Despite setbacks in the Phase 3 EVOKE Alzheimer's trial, ongoing trials like LIGHT-MCI and OxSENSE continue to explore neurobiological mechanisms beyond metabolic effects.
Comprehensive review examining GLP-1 receptor agonists for neurological conditions. A recent NEJM trial showed GLP-1 treatment resulted in less motor disability progression at 12 months.
A comprehensive NeurologyLive review examines evidence for repositioning GLP-1 drugs across neurological conditions. Exenatide and lixisenatide show motor benefits in Parkinson's disease, while GLP-1 agonists reduced intracranial pressure and migraine days in idiopathic intracranial hypertension. The semaglutide EVOKE trials in Alzheimer's failed clinically despite modest biomarker improvements.